The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | BET inhibition for the treatment of myelofibrosis
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses moving beyond single-agent JAK inhibition in myelofibrosis (MF), specifically commenting on the potential for the inhibition of bromodomain and extra-terminal motif (BET) proteins. The BET inhibitor pelabresib has been tested in a large Phase III clinical trial (MANIFEST-2; NCT04603495), showing encouraging efficacy and comparable outcomes to well-established ruxolitinib therapy. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support/advisory board participation: Cogent, GSK, Morphosys, PharmaEssentia.
